Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 07, 2015 3:27 AM ET

Pharmaceuticals

Company Overview of MedImmune, LLC

Company Overview

MedImmune, LLC, a biologics research and development company, researches, develops, and explores medicines for unmet medical needs across therapeutic areas, including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines worldwide. It offers Synagis (palivizumab), a monoclonal antibody to prevent serious lower respiratory tract disease; FluMist Quadrivalent (Influenza Vaccine Live, Intranasal), a quadrivalent influenza vaccine; and Trivalent FluMist (T/LAIV), a live attenuated influenza vaccine. The company was incorporated in 1987 and is based in Gaithersburg, Maryland with locations in Mountain View, Santa Clar...

One MedImmune Way

Gaithersburg, MD 20878

United States

Founded in 1987

2,359 Employees

Phone:

301-398-0000

Fax:

301-527-4200

Key Executives for MedImmune, LLC

Vice President of Finance
Chief Operating Officer
Vice President, Head of Antibody Discovery and Protein Engineering and Global Head of Technology
Senior Vice President of Biopharmaceutical Development
Age: 60
Executive Vice President
Compensation as of Fiscal Year 2015.

MedImmune, LLC Key Developments

MedImmune, LLC Presents at BIO International Convention 2015, Jun-16-2015 02:30 PM

MedImmune, LLC Presents at BIO International Convention 2015, Jun-16-2015 02:30 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States.

MedImmune, LLC Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 08:40 AM

MedImmune, LLC Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 08:40 AM. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Speakers: Reginald Seeto, Head of Partnering & Strategy and Vice President.

AstraZeneca and MedImmune Enter into an Exclusive Collaboration with Celgene Corporation for the Development and Commercialisation of MEDI4736

AstraZeneca and MedImmune announced that they have entered into an exclusive collaboration agreement with Celgene Corporation, for the development and commercialisation of MEDI4736 across a range of blood cancers including non-Hodgkin's lymphoma, myelodysplastic syndromes and multiple myeloma. Under the terms of the agreement, Celgene will make an upfront payment of $450 million to AstraZeneca in relation to MEDI4736. Celgene will lead on development across all clinical trials within the collaboration and will take on all research and development costs until the end of 2016, after which they will take on 75% of these costs. Celgene will also be responsible for global commercialisation of approved treatments. AstraZeneca will continue to manufacture and book all sales of MEDI4736 and will pay a royalty to Celgene on worldwide sales in haematological indications. The royalty rate will start at 70% and will decrease to approximately half of the sales of MEDI4736 in haematological indications over a period of four years. MEDI4736 is an investigational immune checkpoint inhibitor, directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumours avoid detection by the immune system. MEDI4736 blocks these signals, countering the tumour's immune-evading tactics. Within the collaboration, MEDI4736 will be assessed both as monotherapy and in combination with other AstraZeneca and Celgene potential and existing cancer medicines. Over time, the collaboration could expand to include other assets.

Similar Private Companies By Industry

Company Name Region
Novartis Corporation United States
BPT Pharmaceuticals Inc. United States
Angiotech Pharmaceuticals (US), Inc. United States
Astarix Institute United States
Scherer R P International Corp United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 4, 2014
Definiens AG
Merger/Acquisition
August 20, 2014
MedImmune, LLC, Global Rights to Ethyol®
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MedImmune, LLC, please visit www.medimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.